Two Young Researchers from US Institutions among the Six Winners of the 12th Edition of the Fellowships Promoted by IBSA Foundation for Scientific Research
The award ceremony was held today in Milan (Italy), where the 2025 call for proposals was also officially launched.
PARSIPPANY, N.J., May 27, 2025--(BUSINESS WIRE)--Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships program, which for over a decade, has supported talented young researchers from universities and research institutions around the world. The program awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; and has been a constantly growing success, as demonstrated by the 259 applications received for the 2024 edition, which marked a new record, across five therapeutic areas.
This year, the scientific board of IBSA Foundation selected, among others, two young researchers from Californian research institutes: Vanessa Lopez Polo, Ph.D. (University of California, San Francisco), 32, and of Spanish origins, and Enchen Zhou, Ph.D. (University of California San Diego), 34, of Chinese heritage.
Vanessa Lopez Polo, a researcher at the Cardiovascular Research Institute UCSF, received the award in the Healthy Aging/Regenerative Medicine category for her project "Exploring the role of macrophage-mediated heterophagy in aging and its potential for enhancing tissue health," which investigates heterophagy, a key cellular quality control mechanism essential for tissue homeostasis. The project aims to understand how aging affects this process and how new therapies might be developed to promote healthy aging by modulating the immune system.
Enchen Zhou, who is based at the Glass Laboratory – UC San Diego, was awarded in the Endocrinology category for his project "Targeting Intestinal-Specific Transcription Factors to Enhance GLP-1 Release: A Novel Approach for Treating Obesity, Diabetes, and MASLD." This study focuses on improving the regulation of glucagon-like peptide 1 (GLP-1), a key therapeutic target for cardiometabolic diseases such as obesity and diabetes.
"More than ever, it is critically important that we support young and talented researchers in their scientific endeavors. Here at IBSA, we are proud that our Foundation awards these fellowships so that these researchers can conduct cutting-edge science that can work towards improving patients' lives," stated Carolyn Kong, PharmD, Chief Business and Medical Affairs Officer, IBSA USA.
Since its launch in 2012, the IBSA Foundation Fellowship program has attracted increasing interest, with 1,645 project submissions from researchers under the age of 40 and from 60 countries. Over twelve editions, 58 projects have been funded, totaling €1.6 million. Each fellowship, now worth €32,000, is awarded to research projects in five traditionally underexplored scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/rheumatology/orthopedics and healthy aging/regenerative medicine. A particularly noteworthy statistic is the high number of submissions from female researchers: 1,041 out of 1,645 applications, or around 63%, which testifies to their increasingly central role in international scientific research.
"Supporting the talent of young researchers represents for IBSA Foundation a strategic investment, driving scientific progress and fostering a society that is more aware and better equipped to face future challenges. In a context where access to a scientific career is increasingly complex, our Fellowships serve as a tangible tool to recognize merit and promote innovation," stated Silvia Misiti, Director of IBSA Foundation for scientific research.
At the Milan (Italy) event, IBSA Foundation announced the opening of the call for proposals for the 2025 Fellowships. As previously held in 2024, the new edition will award six €32,000 grants in the same five scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/rheumatology/orthopedics and healthy aging/regenerative medicine. The sixth scholarship will be assigned to the category that receives the highest number of applications.
Beginning this year, the IBSA Foundation Research Equity Prize will also be introduced: worth €5,000, the prize will be awarded to the best scientific project developed in a laboratory, research institute, or university based in a developing country.
Researchers wishing to apply must submit their proposals by January 31, 2026, through the platform.
About IBSA
IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people.
About IBSA Foundation for scientific research
Established in 2012 in Lugano by the pharmaceutical company IBSA (Institut Biochimique SA), IBSA Foundation for scientific research is the main promoter of IBSA Group's social responsibility activities.
The Foundation promotes "Science for all" through accessible information and activities that unite scientific and humanistic culture. Its initiatives include high-level forums featuring internationally renowned scientists, educational events, conferences on art-and-science and health-and-culture and research scholarships in various areas of basic and clinical research.
PM-1113-v2 (v2.0)
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526862222/en/
Contacts
For further information: Daina Basile, Kovak-Likly Communicationsdbasile@klcpr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
12 minutes ago
- Business Insider
Mark Cuban says the US has got to keep investing in research if it wants to have a chance of beating China at AI
"Shark Tank" star Mark Cuban says the US can beat China at AI if it continues "investing in research of all kinds as a country." "The IP we create domestically is what the frontier models can buy or invest in to define their differentiation and advance forward," Cuban wrote on X in response to a post by David Sacks, the White House's AI and crypto czar, on the state of the AI race. When asked about his X post, Cuban told Business Insider that American research is "important, not just because of the outcome of the research itself, but its value to American frontier AI models" like ChatGPT and Gemini. Cuban said that any unique intellectual property produced can be "licensed to the models, for a fee, to be included in their training." This would not only offset research costs but also make the models more valuable, he added. "The quality and depth of the research we do in this country can help us stay ahead of China and other countries in the AI race," Cuban told Business Insider. "We need our Ph.D.s, our scientists, our experts, to stay here and contribute to society, and their IP to make American AI models the global leaders," he added. Since taking office in January, President Donald Trump's administration has been culling research grants for universities and research institutions like the National Institutes of Health (NIH). Please help BI improve our Business, Tech, and Innovation coverage by sharing a bit about your role — it will help us tailor content that matters most to people like you. What is your job title? (1 of 2) Entry level position Project manager Management Senior management Executive management Student Self-employed Retired Other Continue By providing this information, you agree that Business Insider may use this data to improve your site experience and for targeted advertising. By continuing you agree that you accept the Terms of Service and Privacy Policy . Researchers and scientists told Business Insider's Ayelet Sheffey in April that the cuts could stifle innovation and result in brain drain. "It absolutely endangers the United States' position as the global leader in medical research. And for that, we will pay," Peter Lurie, a recipient of an NIH grant terminated in March, told Sheffey. Staying ahead in the AI race has been a primary focus for the Trump administration, which unveiled its " AI Action Plan" last month. The 28-page plan calls for a light-touch approach to AI regulation compared to Trump's predecessor, President Joe Biden. In January, Chinese AI startup DeepSeek shocked the world with its high-performing but relatively cheap AI models. Trump said he viewed DeepSeek's accomplishment "as a positive, as an asset" for America. "The release of DeepSeek, AI from a Chinese company, should be a wake-up call for our industries that we need to be laser-focused on competing to win," Trump told GOP lawmakers in January.
Yahoo
5 hours ago
- Yahoo
Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain
Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 /PRNewswire/ -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep experience in the Spanish medical market, but also due to the trust and commitment of their team. Brain Navi CEO Jerry Chen stated, "Brain Navi is proud to work alongside a partner that shares our vision of surgical innovation and desire to improve the well-being of patients continuously." At this year's SENEC Congress, Spain's leading annual event hosted by the Spanish Society of Neurosurgery, which gathers experts from across the country to share the latest scientific advances and clinical innovations in the field, Spanish neurosurgeons had the opportunity to witness NaoTrac, Brain Navi's neurosurgical navigation robot, in action. Alongside Palex, Brain Navi showcased its technology throughout the event. Surgeons from all around Spain expressed strong interest in NaoTrac's capabilities and potential applications in their hospitals. "Spain holds great promise as a hub for neurosurgical innovation," said Carles Calaf, Director of the Neurosciences Business Unit at Palex Healthcare. "At SENEC, we witnessed firsthand how strongly surgeons responded to the need for more intelligent, AI-powered tools in the OR. This aligns with our belief that technology like NaoTrac can genuinely enhance surgical precision and support clinical teams in delivering better outcomes. With Brain Navi as our partner, we are confident this is only the beginning of helping more hospitals — and more patients — across Spain." Just one week after the congress, the first NaoTrac system was installed in a Spanish hospital, where neurosurgeons, supported by Brain Navi and Palex teams, performed the country's first surgeries using the NaoTrac. The surgeons were highly impressed by NaoTrac's precision and intuitive design, highlighting its user-friendliness and value as a powerful asset in the Operating Room. "At Palex, our mission is to bring cutting-edge medical technology closer to those who need it most," said Eulàlia Llopis, General Manager of the Hospital Area at Palex. "Collaborating with Brain Navi reflects our commitment to supporting clinicians with solutions that truly make a difference — in precision, efficiency, and above all, patient care." For Brain Navi, this marks a major milestone in our global expansion, reinforcing the mission to improve patient outcomes through advanced medical technologies and to empower surgical teams with the best tools available. View original content to download multimedia: SOURCE Brain Navi Biotechnology Co., Ltd.
New York Post
15 hours ago
- New York Post
Ozempic users aged backwards by more than 3 years in new trial
An astonishing new trial suggests that Ozempic may help users not only drop pounds but also turn back time. In the first trial to directly measure the impact of semaglutide on aging, half of the participants were given a weekly injection of Ozempic while the other half received a placebo for 32 weeks. 'Those on semaglutide drug became, on average, 3.1 years biologically younger by the end of the study,' diagnostic researcher Varun Dwaraka reported. The placebo group showed no significant change in biological age over the same period. Researchers believe these powerful anti-aging qualities are related to Ozempic's effect on fat distribution and metabolic health. millaf – While everyone knows their chronological age, medical experts often speak in terms of biological or 'phenotypic' age, which measures factors like metabolism, inflammation, and organ function. Researchers note that the anti-aging effects of GLP-1 varied across the body's systems. The most dramatic improvements were to the brain and inflammatory system, where the drug, originally developed to treat diabetes, appeared to delay biological aging by nearly 5 years. The teams also noted significant improvement in the heart and kidneys. 'The drug may not only slow the rate of aging, but in some individuals partially reverse it,' Dwaraka said. Researchers believe these powerful anti-aging qualities are related to Ozempic's effect on fat distribution and metabolic health. In essence, excess fat around the body's organs promotes the release of pro-aging molecules. Obesity causes low-grade chronic inflammation, which is when the body's natural chemical response to an irritant or injury remains active long after the threat has passed. GLP-1 drugs indirectly reduce inflammation through weight loss. The meds can also activate specific T cells — white blood cells key to the immune system — which can have anti-inflammatory effects. 'The drug may not only slow the rate of aging, but in some individuals partially reverse it,' a researcher on the study said. Ilzer/ – By reducing excess fat and inflammation, two hallmarks of epigenetic aging, the drug effectively slows the cruel march of deterioration. The use of GLP-1 medications has proliferated in recent years. A recent KFF health poll revealed that 12% of US adults have taken an Ozempic-like drug at some point. Despite the promising results, Dwaraka said caution and patience are called for. 'Prescribing it more broadly as an anti-ageing therapy is premature,' he said. However, he and his team are hopeful their research will inspire further studies and support the repurposing of existing drugs to treat age-related problems, as these established medications are more likely to be fast-tracked for approval and come without the risk of unforeseen side effects. 'Semaglutide may well emerge as one of the most promising candidates in this space,' Dwaraka concluded. GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk and decreased cancer risk to addiction treatment.
